Nucryst appoints new VP of research

June 14, 2006 – NUCRYST Pharmaceuticals Corp. of Wakefield, Mass., announced that Katherine Turner has been appointed vice president of research.

Turner will be responsible for leading NUCRYST’s pharmaceutical research and will report to Paul Schechter, vice president of drug development and regulatory affairs and chief medical officer.

Most recently Turner served as vice president, validation biology at Biogen Idec Inc., where she directed research in immunology, neurobiology, fibrosis and oncology. Prior to this, she rose through positions of increasing responsibilities at Genetics Institute and its successor, Wyeth, to vice president, immunology and memostasis.

POST A COMMENT

Easily post a comment below using your Linkedin, Twitter, Google or Facebook account. Comments won't automatically be posted to your social media accounts unless you select to share.